Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06102915

Enrollment

289

Registered

2023-10-26

Start date

2023-08-01

Completion date

2023-11-23

Last updated

2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Grafting, Coronary Artery Disease, Hypothermic Cardiopulmonary Bypass, Neuromuscular Blockade, Postoperative Pulmonary Atelectasis, Postoperative Pulmonary Complication

Keywords

Neuromuscular Blockade, Postoperative Pulmonary Atelectasis, postoperative pulmonary complication, Coronary Artery Disease, coronary artery bypass grafting, hypothermic cardiopulmonary bypass, rocuronium, cis-atracurium

Brief summary

The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.

Interventions

DRUGRocuronium Bromide 10 MG/ML

Comparative

DRUGNimbex 10 MG in 5 ML Injection

Comparative

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients that undergo general anaesthesia for CABG surgery requiring neuromuscular blockade of either rocuronium or cis-atracurium

Exclusion criteria

1. Recent history of pulmonary infection four weeks before surgery 2. Exposed to both neuromuscular blockade within 24 hours perioperatively 3. Patients intubated or on tracheostomies pre-operatively 4. Any missing or incomplete data

Design outcomes

Primary

Measure	Time frame	Description
Incidence of postoperative pulmonary complication	6 months	Which neuromuscular relaxant is associated with lesser postoperative pulmonary complication

Secondary

Measure	Time frame	Description
Ventilation hours in ICU	6 months	Ventilation hours from ICU admission from OR to extubation
Requirements for Non-invasive ventilation	6 months	NIV duration
Incidence of postoperative atrial fibrillation	6 months	Incidence of postoperative atrial fibrillation

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026